NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib - Kießling, Michael; Nicolay, Jan Peter; Schlör, Tabea; Klemke, Claus-Detlev (OncoTarget, 2017)
Gesehen am 28.05.2018